George Church Enters X-Prize Fray

Jeff Perkel, a past editor at The Scientist, reports: It would seem that, when it comes to the Archon X Prize for Genomics, George Church has had a change of heart. The $10 million prize will go to the first group that can sequence 100 genomes (to at least 98 percent coverage and with less than one error per 100,000 bases) in 10 days, for under $10,000 per genome. linkurl:Last year,;http://www.the-scientist.com/article/display/36685/ Church, a Harvard geneticist and DNA sequencing pioneer, tol

Written byAlla Katsnelson
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Jeff Perkel, a past editor at The Scientist, reports: It would seem that, when it comes to the Archon X Prize for Genomics, George Church has had a change of heart. The $10 million prize will go to the first group that can sequence 100 genomes (to at least 98 percent coverage and with less than one error per 100,000 bases) in 10 days, for under $10,000 per genome. linkurl:Last year,;http://www.the-scientist.com/article/display/36685/ Church, a Harvard geneticist and DNA sequencing pioneer, told The Scientist that he would not be competing. Church planned instead to focus on his "Personal Genome Project," an attempt to sequence one percent of the genome sequence from each of '10 individuals this year and a million individuals as soon as possible.'" But, Church said then, "If we wake up one morning and say we can snatch up $10 million easily, I don't think anyone's going to turn that down." Apparently, that morning has finally arrived. GenomeWeb linkurl:reported;http://www.genomeweb.com/issues/news/143758-1.html] today that Church has officially entered the race. His group, the Personal Genome X-Team, will be competing against five other teams, according to the linkurl:Boston Globe:;http://www.boston.com/business/globe/articles/2007/12/04/x_games_for_scientists_offers_10m_top_prize/?page=1: 454 Life Sciences, Reveo Inc., VisiGen Biotechnologies Inc., the Foundation for Applied Molecular Evolution, and Base4innovation Ltd. Church's strategy, according to GenomeWeb, "will employ a combination of multiplex linkurl:polony;http://www.the-scientist.com/article/display/14448/ sequencing strategy and haplotyping." In the meantime, Church continues work on the Personal Genome Project. Ten individuals (the "PGP-10") have already agreed to release their sequence, medical, and personal information; the Project linkurl:Web site;http://www.personalgenomes.org/ claims it will begin enrolling members of the general public starting in early 2008.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies